Wacker

Photo
03.06.2024 • News

Wacker Buys Manufacturing Assets and Know-how of Bio Med Sciences

In a move to expand its expertise and business in silicone-coated healthcare products, Germany’s Wacker Chemie has acquired the manufacturing assets and know-how of US-based Bio Med Sciences. As part of the acquisition, a majority of Bio Med Sciences’ workforce will also move to Wacker, the company said. Financial details of the transaction were not disclosed.

Photo
27.09.2023 • News

Wacker Expands Capacity for Specialty Silicones in China

Wacker Chemie started the construction of several new production lines to expand its specialty silicone manufacturing capacities at the Zhangjiagang site in Jiangsu Province, China. At the site, which is one of Wacker’s largest fully integrated production sites, the globally operating chemical group will produce functional silicone fluids, silicone emulsions and silicone elastomer gels. Investments of some €150 million are planned for the expansion project, Wacker said.

Photo
11.05.2023 • News

Wacker Buys All of ADL BioPharma from Private Equity

German chemical group Wacker has acquired 100% of ADL Biopharma from private equity investor Kartesia for a price said to exceed €100 million. It now owns the entire 150,000 m2 production site in the northern Spanish city of Léon with fermentation capacity of just under 3,000 cbm (gross volume).

Photo
04.04.2023 • News

Wacker and CordenPharma in RNA Drugs Project

Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), German companies Wacker Chemie and CordenPharma International have launched a three-year project to accelerate the development of RNA-based drugs.

Photo
21.06.2022 • News

Wacker has Ambitious Plans for Norwegian Site

With an eye to expanding production capacity for silicon metal, Germany’s Wacker Chemie has launched a feasibility study to carry out a capacity upgrade at its site in Holla, Norway.

Photo
16.05.2022 • News

Wacker Opens new R&D Center in Michigan

Wacker Chemie has opened a new US regional innovation center in Ann Arbor, Michigan, dedicated to developing high-margin biotech and silicone specialties for high-tech applications. The site will also serve as headquarters of Wacker Chemical Corporation, responsible for its business in North and Central America.

Photo
12.04.2022 • News

Six Firms to Make Vaccines for German Emergency Supply

Germany’s economics ministry has budgeted up to €2.9 billion ($3.14 billion) to ensure sufficient supply of mostly mRNA-based Covid-19 vaccines to be able to deal with the ongoing pandemic and any future outbreaks up to 2029.

Photo
03.02.2022 • News

Wacker’s Siltronic Deal with GlobalWafers Off

With Germany’s foreign trade clearance still missing on the deal’s agreed Jan. 31 closing date, Munich-based Wacker Chemie declared its plans to sell its remaining 30.8% stake in silicon wafers manufacturer Siltronic to Taiwan’s GlobalWafers officially dead. For now, at least.

Photo
18.01.2022 • News

Siltronic Sale to GlobalWafers Looks Shaky

GlobalWafers’ planned takeover of Wacker Chemie’s remaining 30.8% stake in silicon wafers manufacturer Siltronic is looking somewhat shaky as the German economics ministry – following a year’s review of the plans – apparently remains unconvinced that the $5.3 billion deal is in the national interest.

Photo
14.01.2022 • News

Wacker and Biosyntia Partner on Biotin

German chemical company Wacker has signed a contract with Danish biotech Biosyntia to develop a large-scale production process for biotin based on the fermentation of plant-based raw materials. This would provide a sustainable alternative to the synthetic version that is currently on the market and made from petrochemicals.

Photo
16.12.2021 • News

Wacker and CordenPharma in Lipid Nanoparticles Partnership

German chemical company Wacker and compatriot CDMO CordenPharma have agreed to jointly develop know-how and processes for manufacturing lipid nanoparticles (LNP) to meet growing market demand. Both companies will first build up R&D capacities at their respective sites – Wacker in Amsterdam, the Netherlands, and CordenPharma in Caponago, Italy.

Photo
29.10.2021 • News

Wacker Takes Majority Stake in China Silane Firm

German chemical company Wacker has acquired a 60% stake in Chinese specialty silane producer SICO Performance Material for an undisclosed sum. The transaction is expected to close in the first half of 2022 once the necessary regulatory and antitrust approvals have been received.

Photo
15.09.2021 • News

CureVac Cancels two Vaccine Manufacture Deals

German biotech CureVac has canceled manufacturing contracts with two prospective partners for its Covid-19 vaccine CVnCoV while retaining others. The company said on Sept. 14 it would end the arrangements with Germany’s Wacker Chemie and Switzerland’s Celonic Group, but leave the deals with Rentschler Biopharma and Novartis intact.

Photo
13.07.2021 • News

Lanxess and Wacker Join Foundation 2°

Lanxess and Wacker have become the first two chemical companies to join Foundation 2°, a German corporate initiative lobbying for effective market-based conditions for climate protection and recognition of the “problem-solving skills of German companies.”

Photo
17.03.2021 • News

CO2-Neutral Chemical Industry

The European Chemical Industry has set out on an ambitious path to become carbon neutral. Germany, as one of the major chemical manufacturing nations, has committed to achieve this goal by 2050.

Photo
05.02.2021 • News

Wacker Chemie to Buy California CDMO Genopis

German chemical producer Wacker Chemie is acquiring 100% of San Diego, California- headquartered CDMO Genopis from its two South Korean owners, Helixmith and Medivate Partner, both based in Seoul.

Photo
11.12.2020 • News

Wacker to Sell Siltronic Stake to GlobalWafers

Germany’s Wacker Chemie is selling its remaining 30.8% stake in semiconductor specialist Siltronic to GlobalWafers. As part of the transaction, which is subject to regulatory approval, the Taiwan-based company will offer Siltronic shareholders a price of €125 per share, with a minimum acceptance threshold of 65% of outstanding shares.

Photo
26.11.2020 • News

Wacker CDMO Arm to Produce CureVac Vaccine

Germany’s Wacker Chemie has signed a contract to manufacture the active substance for compatriot CureVac’s Covid-19 vaccine candidate CVnCoV. Under the terms, the biotech arm of the Munich-based chemical group will ramp up GMP production of the mRNA drug substance for the candidate at its Amsterdam site in the first half of 2021.

Photo
16.10.2020 • News

Wacker Invests in China Site

German chemical company Wacker Chemie is investing about $100 million to build two new manufacturing plants at its site in Nanjing, China.

Photo
31.07.2020 • News

Wacker Biotech Invests in Amsterdam Site

Wacker Biotech, CDMO subsidiary of the Munich-based chemical group, is investing a mid-double-digit-million euro sum in its production facilities for biologics, LMPs (live microbial products) and vaccines at the Amsterdam site it acquired two years ago.

Photo
15.06.2020 • TopicsStrategy

Circular Economy

The chemical industry is on the threshold of a new era – the age of circularity. We asked industry experts to share their opinions on this transformational topic.

78 more articles

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis